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TO THE EDITOR
Psoriasis is a chronic immune-mediated
and hyperproliferative disorder of the
skin that affects 2–3% of the population.
Psoriasis is associated with an increased
incidence of several cardiovascular and
metabolic comorbidities, including cor-
onary artery disease (CAD), hyper-
tension, obesity, hyperlipidemia, and
type 2 diabetes (T2D) (Davidovici
et al., 2010). The association of these
cardiovascular and metabolic diseases
with psoriasis could be due to shared
genetic risk variants, shared environ-
mental triggers, activation of common
inflammatory pathways, or a combina-
tion of these factors. Here, we evaluated
the hypothesis that some of the increa-
sed risk for cardiovascular and meta-
bolic diseases in psoriasis is derived
from shared genetic risk factors.
Using the genome-wide association
studies (GWAS) catalog (available at
www.genome.gov/gwastudies and acc-
essed in December 2011), we selected
363 single-nucleotide polymorphisms
(SNPs) that showed significant associa-
tion with CAD, hypertension, body mass
index (BMI), hyperlipidemia (total, low-
density lipoprotein (LDL), and high-den-
sity lipoprotein (HDL) cholesterol levels
and triglyceride levels), or T2D. Selected
SNPs met genome-wide significance
(Po5108) in at least two GWAS or
were significant in the latest meta-ana-
lysis of GWAS. Additional SNPs or loci
were also included on the basis of latest
expert opinions (McCarthy, 2010;
O’Donnell and Nabel, 2011; Peden
and Farrall, 2011). Detailed information
about the selected SNPs is provided in
Supplementary Table S1 online.
We evaluated the selected cardio-
vascular and metabolic SNPs for asso-
ciation with psoriasis in four psoriasis
GWAS cohorts: the GAIN cohort includ-
ing 1,368 psoriasis cases and 1,348
controls (Nair et al., 2009), an
unpublished psoriasis cohort from
Sweden including 725 cases and 438
controls, a Washington University/
University of California San Francisco
cohort including 211 psoriasis cases and
502 controls (Liu et al., 2008), and the
Wellcome Trust Case–Control Consor-
tium cohort including 2,178 psoriasis
cases and 5,175 controls (Strange et al.,
2010). Further details of the Swedish
cohort are described in the Supple-
mentary Methods online. IMPUTE2 was
used to impute the ungenotyped SNPs
using phase 3 HapMap and 1,000 Gen-
omes pilot project CEU haplotypes as a
reference. SNPTEST was used to associ-
ate the imputed dosage for each SNP
with psoriasis status separately in each
study population with adjustment of
the first three principal components
from a multidimensional scaling
analysis of population stratification.
The association test results for these
SNPs with relatively high confidence
(PROPER_Info40.5) were then com-
bined by meta-analysis with the META
using the inverse-variance method based
on a fixed-effect model. The false dis-
covery rate method was used to correct
for multiple testing (FDR_qo0.05).
We first examined the associations
between all selected SNPs and psoriasis
status (Table 1 and Supplementary
Table S2 online). After adjusting for
multiple testing with the false discovery
rate method, seven SNPs were found
to be associated with psoriasis status
(FDR_qo0.05, Table 1). The alleles
associated with increased risk for
dyslipidemia (rs2247056, rs3177928,
rs492602, and rs181362), increased
blood pressure levels (rs805303,
rs653178, and rs3184504), and increa-
sed risk for CAD (rs3184504) were ass-
ociated with increased risk for psoriasis
(Table 1). The top three SNPs
(rs2247056, rs3177928, and rs805303)
were located in the HLA gene region,
which is a known psoriasis susceptibility
locus. After further adjustment for the
top psoriasis risk allele HLA-C*06:02
(determined by imputation as described
in Chen et al., 2012), the associa-
tions for rs2247056 and rs3177928
were mitigated (P¼ 0.06 and 0.07,
respectively), whereas the association
for rs805303 persisted (P¼ 0.005). As
multiple psoriasis risk alleles are
Abbreviations: BMI, body mass index; CAD, coronary artery disease; GWAS, genome-wide association
studies; HDL, high-density lipoprotein; LD, linkage disequilibrium; LDL, low-density lipoprotein; SNP,
single-nucleotide polymorphism; T2D, type 2 diabetes; wGRS, weighted gene risk score
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identified in HLA loci (Chen et al.,
2012), we cannot rule out that the
significant association for rs805303 is
derived from linkage disequilibrium (LD)
with other psoriasis HLA risk alleles.
Interestingly, we identified four non-
HLA SNPs with evidence of shared
genetic risk between psoriasis and
cardiovascular and metabolic diseases:
rs492603 in FUT2, rs181362 in
UBE2L3, and rs653178 and rs3184504
(in complete LD with each other) near or
in SH2B3. FUT2 encodes an alpha-
(1,2)fucosyltransferase that determines
the secretor status of blood group
antigens on epithelial cells and in
bodily secretions and has been recently
associated with susceptibility to psoriasis
and Crohns’s disease (Ellinghaus et al.,
2012), type 1 diabetes (Smyth et al.,
2011), primary sclerosing cholangitis
(Folseraas et al., 2012), and norovirus
infection (Carlsson et al., 2009). UBE2L3
encodes an ubiquitin-conjugating
enzyme involved in cell proliferation
and immune function and is associated
with susceptibility to celiac disease and
rheumatoid arthritis (Zhernakova et al.,
2011), Crohn’s disease (Fransen et al.,
2010), and systemic lupus erythema-
tosus (Wang et al., 2012). The adaptor
protein encoded by SH2B3 has
pleiotropic signaling roles in regulating
lymphocyte differentiation, induction of
VCAM-1 and E-selectin on endothelial
cells by tumor necrosis factor-a, and
thrombus formation (Devalliere and
Charreau, 2011), and thus might
explain its dual role in susceptibility to
multiple autoimmune diseases and
endothelium-related cardiovascular
diseases (Jin et al., 2012).
With a combined 4,482 psoriasis
cases and 7,463 controls, our meta-
analysis had 80% power to detect
genetic variants with OR¼1.2 at a
significance level alpha of 0.05, assum-
ing 5% of the population allele
frequency. Given that many cardiovas-
cular and metabolic trait SNPs have
ORs less than 1.2, we sought to deter-
mine whether cardiovascular and meta-
bolic risk SNPs could be having a real,
but more subtle, effect on psoriasis
susceptibility. We therefore constructed
a weighted gene risk score (wGRS) to
investigate the aggregate effects of the
risk alleles associated with cardiovascu-
lar and metabolic traits between psor-
iasis patients and controls. Prior studies
have shown that such genetic risk
scores, which estimate an individual’s
overall genetic burden, have increased
the ability to discriminate between cases
and controls (Chen et al., 2011). The
GRS was weighted according to the
effect size of the risk alleles, and a
common set of SNPs were examined
across all cohorts (see Supplementary
Methods online). A small but significant
difference for the wGRS of CAD, total
cholesterol levels, and TG levels was
seen (Po0.006 for adjusting for multiple
testing of eight traits, Table 2). The
wGRS of total cholesterol levels did
not reach significance after removing
the top associated SNPs (rs3177928
and rs492602, P¼0.42, Tables 1 and
2). No difference between psoriasis
cases and controls was observed regard-
ing the wGRS of hypertension, T2D,
LDL cholesterol levels, HDL cholesterol
levels, and BMI (Table 2).
Multiple cardiovascular and meta-
bolic comorbidities have been observed
in psoriasis patients. Here we examined
whether the co-manifestation of these
conditions is a result of shared genetic
factors. The data presented here suggest
that patients with psoriasis are enriched
for certain common genetic variants
(HLA, FUT2, UBE2L3, SH2B3) that pre-
dispose to increased risk for
Table 1. Top 10 metabolic SNPs associated with psoriasis status in the meta-analysis of four studies
Chromo-
some SNP
Nearby
gene
Minor/
major
allele
Effect on
metabolic
phenotypes
(allele
effect)1
Effect on psoriasis
(allele effect/P-value)
b/P-value
(meta-
analysis)
OR (95%
CI)
FDR_q
value2
GAIN1,3 Sweden1,3 WashU/
UCSF1,3
WTCCC1,3
6 rs2247056 HLA-C T/C CmTG Cm/3.32E 04 Cm/0.02 Cm/0.45 Cm/4.21E38 0.43/3.25E35 1.53 (1.43–1.64) o 0.0001
6 rs3177928 HLA-DRA A/G AmTC, LDLC Am/5.59E 07 Am/0.07 Am/0.21 Am/2.66E29 0.45/1.20E32 1.57 (1.46–1.69) o 0.0001
6 rs805303 BAT2,
BAT5
A/G AkSBP, DBP,
and HTN
Ak/6.17E 02 Ak/3.42E 01 Ak/7.69E01 Ak/3.13E07 0.15/8.30E07 0.86 (0.81–0.91) o 0.0001
19 rs492602 FUT2 A/G GmTC Gm/3.30E 03 Gm/6.64E 01 Gm/7.16E01 Gm/6.59E05 0.13/8.23E06 1.14 (1.07–1.20) 0.0007
22 rs181362 UBE2L3 T/C Tk/HDLC Tm/1.40E 01 Tm/8.18E01 Tm/2.62E01 Tm/2.77E04 0.14/1.43E04 1.15 (1.07–1.23) 0.0102
12 rs653178 ATXN2,
SH2B3
C/T TkDBP Tk/2.56E 02 Tm/6.65E01 Tk/1.07E02 Tk/5.77E03 0.11/2.08E04 0.90 (0.85–0.95) 0.0124
12 rs3184504 SH2B3 T/C TmCAD, DBP,
SBP
Tm5.60E02 Tk/4.76E01 Tm/1.00E02 Tm/6.51E03 0.10/6.22E04 1.11 (1.04–1.17) 0.0318
12 rs11065987 BRAP G/A GkTC, LDLC Gm/6.61E 02 Gk/8.57E 01 Gm/2.59E02 Gm/2.39E02 0.09/1.81E03 1.09 (1.03–1.16) 0.0811
2 rs7593730 RBMS1 T/C CmT2D Cm/3.01E 01 Cm/8.17E 03 Ck/5.81E01 Cm/1.73E02 0.11/2.34E03 1.11 (1.04–1.19) 0.093
10 rs7901695 TCF7L2 C/T CmT2D Ck/1.87E 01 Ck/3.81E 01 Ck/1.98E01 Ck/4.49E02 0.09/5.26E03 0.92 (0.86–0.97) 0.1881
Abbreviations: CAD, coronary artery disease; CI, confidence interval; DBP, diastolic blood pressure; HDLC, high-density lipoprotein cholesterol levels; HTN,
hypertension; LDLC, low-density lipoprotein cholesterol levels; OR, odds ratios; SBP, systolic blood pressure; SNP, single-nucleotide polymorphism; TC, total
cholesterol levels; T2D, type 2 diabetes; TG, triglyceride levels; WTCCC, Wellcome Trust Case–Control Consortium.
1m/k, Increasing/decreasing effects on relevant metabolic traits and psoriasis risk.
2FDR_q, false discovery rate-adjusted P-value based on 358 SNPs in Supplementary Table S3 online.
3All P-values were adjusted by the first three principal components from a multidimensional scaling analysis of population stratification.
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dyslipidemia, hypertension, and
increased CAD risk itself. Further eva-
luation of these genes and pathways
may be important to elucidate whether
particular subsets of psoriasis patients
carry a higher burden of risk for the
development of these cardiovascular
and metabolic comorbidities.
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TO THE EDITOR
Mastocytosis is a benign tumor with
tumor cells usually located in the skin
and/or bone marrow. It is often caused
by a spontaneous mutation in the exon
17 (D816V) of the c-kit gene, which has
been included in the 2007 WHO clas-
sification system of mastocytosis (Valent
et al., 2007 #5458). Inherited forms of
mastocytosis are rare.
Eight members of a single family
presented to a private allergy outpatient
clinic with a history of flushing and
vertigo owing to unspecific triggers,
such as physical exercise or showering.
Four of them (Figure 1) had brown-
yellowish papules that responded with
a wheal-and-flare reaction to mechan-
ical triggers (positive Darier’s sign). The
serum tryptase levels in all family mem-
bers were far in the normal range
(oo11.4mg dl 1, compared in the
Supplementary Table S1 online). The
presenting family members were two
sisters and one brother (Figure 1: indivi-
duals III2, III6, and III4). All of them had
symptomatic children as well (IV1, IV2,
IV5, and IV6). Patient IV1 was the most
severely affected individual, with attacks
of severe genital angioedema up to
twice a week. Skin punch biopsies from
patient III6 and her niece IV1 affirmed
the clinical diagnosis cutaneous masto-
cytosis (CM) (Figure 2a) with a condition
suspicious of mast cell activation syn-
drome (sMCAS, (Hamilton et al., 2011
#5461; Valent et al., 2012 #9305))
consisting in episodes of severe hypo-
tension, flushes, and angioedema. The
patients were diagnosed as suffering
from CM with sMCAS.
A more detailed analysis of the
family’s pedigree revealed that more
ancestors also suffered from a sMCAS
with episodes of flushing, fainting, and/
or diarrhea (I1 and II2 in Figure 1), all of
whom responded well to symptomatic
therapy with H1-antihistamines. The
mother (II2) and the grandfather (I1) both
reported having suffered from brownish
papules in their youth that had sponta-
neously dissolved when they had
reached their 30s. Nevertheless, they
occasionally still suffered from sMCAS
owing to unspecific triggers such as cold
water. Examinations in all patients,
including bone marrow examinations
in patient III6 and her brother III4, did
not reveal any organ infestation.
Familial mastocytosis is a rare condi-
tion and only a few families have been
described so far (Valent et al., 2007
#5458). Multiple mutations in the
c-KIT gene associated with mast cell
disorders have been described so far
(Bodemer et al., 2010 #8513;
Molderings et al., 2010 #5411; Wasag
et al., 2011 #8310). The most prominent
is the D816V mutation (Valent et al.,
2007 #5458). Sequencing the c-KIT
gene by PCR in the skin biopsies from
patients III6 and her niece IV1 (Figures 1
and 2b) showed a mutation in exon 18
at position 849 (S849I), which, to our
knowledge, is previously unreported. A
second mutation in exon 18 at position
835 (c-Kit M835K) was found exclu-
sively in the most severely affected
patient IV1. The mutations could be
identified in material derived from skin
biopsies but not in blood samples or
buccal mouth swabs from our patients
Abbreviations: CM, cutaneous mastocytosis; FFPE, formalin-fixed paraffin-embedded; sMCAS, suspected
mast cell activation syndrome
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